Fig 1.
Notes: HPV = Human papillomavirus; PSA = prostate specific antigen; MRI = Magnetic resonance imaging; DRE = digital rectal examination; TRUS = trans-rectal ultrasound; LDCT = Low dose Computed Tomography; FNA = Fine needle aspiration; FOBT = fecal occult blood testing; FIT = fecal immunofluorenscence testing.
Table 1.
Checklist for quality appraisal.
Fig 2.
PRISMA flow chart of study selection process.
Table 2.
Overview of the included studies (n = 38).
Fig 3.
Overview of quality appraisal result per individual criteria.
Fig 4.
Disutility values in screening phase.
Notes:1) Green color = high quality; Yellow color = medium quality; Grey color = low quality 2) with * values from experts; without * form general population.
Fig 5.
Disutility values for false positive in diagnostic work up phase.
Notes: 1) Green color = high quality; Yellow color = medium quality; Grey color = low quality 2) with * values from experts; without * form general population.
Fig 6.
Procedure-wise disutility values in diagnostic work up phase.
Notes: 1) Green color = high quality; Yellow color = medium quality; Grey color = low quality 2) with * values from experts; without * form general population 3) Different protocol: Conservative process includes observation, surveillance, follow-up with pap smear tests, aggressive process includes early colposcopy, immediate HPV tests.
Fig 7.
Abnormal result related disutility values in diagnostic work up phase.
Notes: 1) abnormal result includes borderline or mildly dyskaryotic (BMD), cervical dysplasia, atypical squamous cells of undetermined significance (ASCUS), low-graded squamous intraepithelial lesion (LSIL), high—graded squamous intraepithelial lesion (HSIL), cervical intraepithelial neoplasia (CIN), Human papillomavirus positive 2) Green color = high quality; Yellow color = medium quality; Grey color = low quality; Dark color = very low quality 3) with * values from experts; without * form general population.
Table 3.
Summary on measured disutility studies by typology and cancer types.
Table 4.
Overview of the estimated disutility values.